2017 Annual Meeting | PL9 - Invited Science: Neuro-oncology
| 01:00 PM - 01:20 PM | Speaker |
ACT IV: An International, Double-blind, Phase 3 Trial of Rindopepimut in Newly Diagnosed, EGFRvIII-expressing Glioblastoma
Michael Weller, MD |
| 01:20 PM - 01:40 PM | Speaker |
Targeting Carcinoma–astrocyte Gap Junctions in Brain Metastasis
Mariza Daras, MD |
| 01:40 PM - 02:00 PM | Speaker |
Single-cell Profiling of Glioblastoma Biopsies Identifies a Family of Activating PDGF-receptor Deletions
Soeren Mueller, PhD |
| 02:00 PM - 02:20 PM | Speaker |
Transformation of Tumor Endothelial Cells to Mesenchymal Stem Cell-like Cells Induces Therapy Resistance in Glioblastoma
Menggui Huang, PhD |
| 02:20 PM - 02:40 PM | Speaker |
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 (Durvalumab [DUR]) in Patients with Glioblastoma (GBM): Results For Cohort B (DUR Monotherapy), Bevacizumab (BEV) Naïve Patients with Recurrent GBM
David Reardon |
| 02:40 PM - 03:00 PM | Speaker |
Redefining the Cellular Architecture of Adult and Pediatric Glioblastomas Through Large-scale Single-cell Analyses
Mariella Filbin, MD, PhD |
| Michael Weller, MD | Dr. Weller has received personal compensation in the range of $0-$499 for serving as a Consultant for Neurosense. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medac. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Philogen. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. Dr. Weller has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Curevac. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orbus. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novocure. The institution of Dr. Weller has received research support from Versameb. |
| Tracy T. Batchelor, MD, MPH | Dr. Batchelor has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Up To Date, Inc. An immediate family member of Dr. Batchelor has received publishing royalties from a publication relating to health care. Dr. Batchelor has received publishing royalties from a publication relating to health care. |
| Mary Welch, MD | Dr. Welch has nothing to disclose. |
| Mariza Daras, MD | Dr. Daras has nothing to disclose. |
| Adrienne Boire, MD, PhD, FAAN | Dr. Boire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apelis Pharmaceuticals. The institution of Dr. Boire has received research support from National Cancer Institute. The institution of Dr. Boire has received research support from Center for Experimental Therapeutics. The institution of Dr. Boire has received research support from STARR Cancer Consortium. The institution of Dr. Boire has received research support from National Cancer Institute. Dr. Boire has received intellectual property interests from a discovery or technology relating to health care. Dr. Boire has received intellectual property interests from a discovery or technology relating to health care. Dr. Boire has received intellectual property interests from a discovery or technology relating to health care. |
| David Reardon | No disclosure on file |
| Menggui Huang, PhD | No disclosure on file |
| Soeren Mueller, PhD | No disclosure on file |
| Mariella Filbin, MD, PhD | No disclosure on file |